Top Markets
Coin of the day
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Peringkat dalam Saham #16900
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Harga Saham
$2.46
Kapitalisasi Pasar
$268.65M
Perubahan (1 hari)
-1.73%
Perubahan (1 tahun)
-57.06%
Negara
CN
Perdagangan VISEN Pharmaceuticals (2561)

Kategori

Jumlah saham beredar untuk VISEN Pharmaceuticals (2561)
Jumlah saham beredar per September 2026: 0
Menurut laporan keuangan terbaru dan harga saham VISEN Pharmaceuticals, jumlah saham beredar saat ini adalah 0. Pada akhir September 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk VISEN Pharmaceuticals (2561) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
Tahun Saham Beredar Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Saham beredar untuk perusahaan serupa atau pesaing